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CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims bene?t of provisional patent 
application Ser. No. 60/110,483 ?led Dec. 1, 1998. The 
entire disclosure of provisional patent application Ser. No. 
60/110,483 is hereby incorporated by reference. 
BACKGROUND 
1. Field of the Invention 
This invention is directed to methods and compositions 
for the oral administration of niacin for the prevention of 
photocarcinogenesis and photoimmunosuppression. 
2. Description of the Background 
Nonmelanoma skin cancers are the most frequent of 
human cancers, approximating 62.5% of the expected inci 
dence for all non-skin cancers combined (Parker, S L et al., 
CA Cancer J Clin 47, 5—27, 1997). Nonmelanoma skin 
cancers have been increasing in incidence at an annual rate 
of 3—6% (Gallagher, R P et al., J Am Acad Dermatol 23, 
413—421, 1990). The increase in nonmelanoma skin cancer 
rate is likely due to an increase in lifetime exposure to UV 
radiation caused by a longer life expectancy and oZone 
depletion (Moseley, H, and Mackie, R M, BritJ Dermatol 
137, 101—103, 1997). Nonmelanoma skin cancers represent 
considerable morbidity (Johnson M L et al., J Am Acad 
Dermatol 11: 930—936, 1984). Both squamous cell carci 
noma and basal cell carcinoma can be invasive and tend to 
present as multiple primary tumors on visible areas of the 
body (KWa, R E, et al.,JAmAcaa' Dermatol 26, 1—26, 1992; 
Miller, S J, JAm Acad Dermatol 24, 1—13, 1991; Miller, S 
J,JAmAcad Dermatol 24, 161—175, 1991; Schreiber, M M, 
J Am Acad Dermatol 23, 1114—1118, 1990). The use of 
sunscreens alone may not be suf?cient protection against 
skin cancer development (Naylor, M F et al.,Arch Dermatol 
131, 170—175, 1995). These observations indicate an 
increasing need for novel skin cancer prevention strategies. 
SUMMARY OF THE INVENTION 
It is an object of the invention to suppress or reverse 
photoimmunosuppression and photocarcinogenesis in a sub 
ject. 
One embodiment of the invention is directed to a method 
for reducing photocarcinogenesis or photoimmunosuppres 
sion in a subject. In the method, one or more oral adminis 
tration of a pharmaceutical composition is given to the 
subject. The pharmaceutical composition comprises niacin 
in an amount effective to reduce photocarcinogenesis or 
photoimmunosuppression. The pharmaceutical composition 
may optionally comprise a pharmaceutically acceptable car 
rier. The method may be used to reduce, eliminate, prevent 
or reverse photocarcinogenesis. Further, the method may be 
used to reduce, eliminate, prevent or reverse photoimmuno 
suppression. 
The subject to be treated may be any animal. Thus, the 
subject may be a mammal, such as, for example, a human. 
The pharmaceutical composition may contain niacin in an 
amount such that the dosage to be administered orally is 
betWeen 1 mg niacin per kilogram of subject Weight to about 
100 mg per kilogram of subject Weight. Preferably, the 
dosage is betWeen 10 mg niacin per kilogram of subject 














The photoimmunusuppression and photocarcinogenesis 
referred to in this application may be caused by natural or 
arti?cial means. Natural means include direct or re?ected 
sunlight. Arti?cial means include all man made ultraviolet 
light sources such as UV lamps, residue UV from lighting 
?xtures, and ultraviolet light emitted from industrial pro 
cesses and methods of manufacture. 
DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts (A) the rate of tumor development in 
UVB/A irradiated mice treated With a diet of 0, 0.1, 0.5 or 
1.0% niacin throughout the study and (B) tumor multiplicity 
in UV-irradiated mice treated With niacin supplementation. 
Values are means +/—SEM. 
FIG. 2. depicts groWth of UVM12 tumor cells in naive 
syngeneic mice after injection of splenocytes from 
UV-irradiated donors treated With niacin supplementation. 
FIG. 3. depicts NAD content in dorsal (A) and ventral (B) 
skin of niacin-supplemented mice. Closed circles represent 
the average skin NAD, relative to protein, of mice that Were 
treated With UV radiation, and an open square represents the 
average skin NAD, relative to protein, of unsupplemented 
and untreated mice. Best-?t, logarithmic curves are shoWn 
for both skin locations; error bars represent standard error. 
DESCRIPTION OF THE INVENTION 
As discussed above, ultraviolet irradiation can cause 
photocarcinogenesis and photoimmunosuppression in 
humans. Current methods of preventing photocarcinogen 
esis and photoimmunosuppression involve the use of sun 
blocks. Sunblock (i.e., sunscreen) refers to any chemical that 
When applied to the skin, reduces the amount of UV light 
that reaches the skin. By preventing UV absorptions, sun 
blocks can prevent photocarcinogenesis and photoimmuno 
suppression. Sunblocks Were originally designed to prevent 
sunburn (also knoWn as erythema), an acute reaction to 
overexposure to the sun. The strength of sunblocks is 
measured by the SPF index (Sun Protection Factor). An SPF 
value of 15, for example, Will provide 15 times the protec 
tion of bare skin to sunburns. HoWever, sunblocks are 
disadvantageous because they require frequent application 
to the skin. Further, every major class of sunblock has been 
linked to skin allergies. 
To overcome the disadvantages of the current methods, 
experiments Were performed to determine if niacin, admin 
istered orally, can decrease photoimmunosuppression and 
photocarcinogenesis. 
One embodiment of the invention is directed to a method 
for reducing photocarcinogenesis or photoimmunosuppres 
sion in a subject. The subject can be any animal, such as a 
mammal. Preferably, the mammal is a human. In the method, 
a pharmaceutical composition comprising niacin in an 
amount effective to reduce photocarcinogenesis or photo 
immunosuppression is administered orally to the subject. 
The method can reduce, eliminate, prevent or reverse pho 
tocarcinogenesis or photoimmunosuppression. 
In a preferred embodiment, the administration comprises 
oral dosages of about 1 mg to about 100 mg per kilogram of 
subject Weight. Preferably, the oral dosage is betWeen about 
10 mg to about 40 mg per kilogram of subject Weight. 
The niacin may be administered With a pharmaceutically 
acceptable carrier. The pharmaceutically acceptable carrier 
may be any carrier knoWn in the ?eld as suitable for 
pharmaceutical oral application. Suitable pharmaceutical 
carriers and formulations are described, for example, in 
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Remington’s Pharmaceutical Sciences (19th ed.) (Genarro, 
ed. (1995) Mack Publishing Co., Easton, Pa.). 
In addition, niacin and the pharmaceutically acceptable 
carrier may be enclosed in a hard or soft shell gelatin 
capsule, compressed into tablets, or incorporated directly 
into the individual’s diet. Speci?cally, niacin may be incor 
porated With excipients and used in the form of ingestible 
tablets, buccal tablets, troches, capsules, elixirs, 
suspensions, syrups, Wafers, and the like. When niacin is 
administered orally, it may be mixed With other food forms 
and pharmaceutically acceptable ?avor enhancers. When the 
niacin agent is administered enterally, they may be intro 
duced in a solid, semi-solid, suspension, or emulsion form 
and may be compounded With any number of Well-knoWn, 
pharmaceutically acceptable additives. Sustained release 
oral delivery systems and/or enteric coatings for orally 
administered dosage forms are knoWn in the art and also 
contemplated. 
It is understood that the photocarcinogenesis or photoim 
munosuppression referred to in this application may refer to 
any carcinogenesis or immunosuppression caused by light. 
The light may be, for example, from natural sources such as 
sunlight or from manmade sources such as a broad spectrum 
light source, a narroWband UV source, UVA source, UVB 
source, or UVC source. 
Other embodiments and advantages of the invention are 
set forth, in part, in the description Which folloWs and, in 
part, Will be obvious from this description and understood by 
the skilled artisan practicing this invention. 
EXAMPLE 1 
Administration of Niacin 
Six-Week-old speci?c-pathogen-free female BALB/ 
cAnNTacfBR (H-2d) mice Were purchased from Taconic 
Laboratory Animals (GermantoWn, NY.) and quarantined 
from tWo Weeks before treatment. Animals Were housed in 
microisolators under barrier conditions With a 12:12-hour 
light-dark cycle at 20+/—2° C. (SD). 
Groups of 25 mice each received the basal diet Which 
consisted of the American Institute of Nutrition 76A rodent 
diet containing 10% corn oil and 30 mg niacin per kilogram 
diet, supplemented With 0, 0.1, 0.5, or 1.0% niacin (Dyets 
Inc. Bethlehem, Pa.). All diets Were pelleted (Dyets Inc.) 
Without heat or steam and stored under refrigeration for less 
than 10 Weeks. Animals Were fed ad libitum and given fresh 
diet three times per Week for three Weeks before UV 
treatments began, and throughout the study. Niacin intakes 
Were calculated from the diet consumed. Animals Were 
supplied With steriliZed Water ad libitum. 
EXAMPLE 2 
UV Irradiation 
The mice Were exposed to UV radiation after three Weeks 
of oral niacin administration. The animals Were shaved 
dorsally With animal clippers each Week. The ?lter tops, 
food, and Water bottles Were removed from the microisola 
tors While mice Were exposed to UV radiation emitted by 
banks of six FS40 Westinghouse ?uorescent sun lamps for 
30 min per day, ?ve days per Week. This UV regimen 
continued for 22 Weeks in the carcinogenesis experiments, 
and for 11 Weeks in the passive transfer assay experiments. 
The cages Were systemically rotated during the study to 
compensate for any differences in ?ux at different positions 
under the lamps. The FS40 lamps emit a continuous spec 
trum from 270 to 390 nm With peak emission at 313 nm. 
About 75% of the energy output is in the Wavelength range 














The total UVB radiation dose Was approximately 1.41><106 
Jm‘2 in the carcinogenesis experiments, and about 0.705>< 
105 Jm'2 in the passive transfer experiments, as measured 
With a UVX Digital Radiometer With a UVX-31 sensor 
(Ultraviolet Products, San Gabriel, Calif.). 
EXAMPLE 3 
Passive Transfer Assay 
The passive transfer assay determines photoimmunosup 
pression by measuring the capacity of a mouse to reject 
antigenic, syngeneic tumors. This assay has been described 
previously (Gensler, H L, Nutr Cancer 29, 157—162, 1997; 
Gensler, H L,] Cancer Res Clin Oncol 117, 345—350, 1991; 
Gensler, H L, Nutr Cancer 22, 121—130, 1994). Brie?y, 
spleens Were excised under aseptic conditions from mice 
after 11 Weeks of UVB treatment. A total of 15 mice per 
group Was used for analysis. The groups consist of (1) the 
0% niacin diet group, (2) the 0.1% niacin diet group, (3) the 
0.5% niacin diet group, and (4) the 1.0% niacin diet group. 
Spleen cells isolated from the spleens Were triturated With 
RPMI 1640 medium Without fetal bovine serum, Washed, 
and resuspended in fresh medium. Splenocytes Were 
injected into the lateral tail veins of 15 naive mice per 
treatment group. Within 24 hours, recipients Were chal 
lenged With about 5><105 UVM12 (syngeneic antigenic 
UV-induced) tumor cells injected intradermally into the 
?anks. Tumor groWth Was measured tWice Weekly With 
vernier calipers. 
EXAMPLE 4 
Tissue Extraction and Assay 
Dorsal and ventral skin samples Were excised from mice 
at 29.5 Weeks after niacin supplementation began. Samples 
Were immediately froZen in liquid nitrogen and stored at 
—80° C. For nicotinamnide-adenine-dinucleotide (NAD) and 
protein analyses, the tissue Was ground to a ?ne poWder in 
liquid nitrogen by mortar and pestle. The poWder Was then 
transferred to a 15 ml centrifuge tube containing 1 ml of 1 
M NaOH. This mixture Was rapidly neutraliZed With 0.27 ml 
of 2 M H3PO4, so that total time in alkali Was less than 2 
min. Next, 0.13 ml of 2 M phenaZine ethosulfate Was added 
to convert NADH to the oxidiZed state (Jacobson, E L, and 
Jacobson, M KMeth Enzymol 280, 221—230, 1997). Finally, 
1.4 ml of 1M HClO4 Was added to precipitate the total 
protein in the sample. Total time from dissolving to per 
chloric acid addition Was less than ?ve minutes. Samples 
Were placed on ice for at least 10 min and centrifuged at 4° 
C. for 10 min at 3000 rpm. Each supernatant Was collected 
and neutraliZed With 1 M KOH/0.33 M K2HPO4. The 
supernatants Were assayed for NAD; the precipitates Were 
dissolved in 1 M NaOH for protein measurement. All 
reagents for these assays Were purchased from Sigma, St. 
Louis, Mo. 
NAD content Was assessed as described previously 
(Jacobson, E L, and Jacobson, M K Meth Enzymol 280, 
221—230, 1997; Jacobson, E L et al., J Cell Physiol 99, 
417—426, 1979). The NAD assay is based on the principle of 
enZymatic cycling betWeen oxidiZed and reduced states, in 
Which NAD is rate-limiting for a series of ampli?cation 
reactions. Control groups, Which received no supplemental 
niacin, consisted of six mice each, Were compared With nine 
or ten mice from the groups Which received niacin supple 
mented diets. The Bradford method (Bradford, M M,Anal 




Differences in primary tumor incidence betWeen the 
experimental groups Were analyZed by the Wilcoxon rank 
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sum test. Analysis of the variance of the data Was performed 
on the passive transfer results to test for a niacin treatment 
effect on the tumor challenge growth rate. Dunnett’s test of 
multiple comparisons Was then used to determine Which 
treatment groups signi?cantly differed in the rate of tumor 
groWth. For the NAD assay, the Q test Was ?rst applied to 
the data to determine Whether questionable values should be 
rejected. This test Was conducted at the 95% con?dence 
level. The data Were then analyZed using the MIXED 
procedure in the statistical analysis program SAS 6.11. The 
MIXED procedure ?ts a variety of mixed linear models to 
data, and a mixed linear model is a generaliZation of the 
standard linear model, With the generaliZation being that the 
data are permitted to exhibit correlation and nonconstant 
variability. In this manner, it Was possible to ?rst account for 
differences and variability in duplicate or triplicate samples 
from the same mouse before the differences betWeen each 
mouse in each group Was compared. This procedure result 
ing in more precise group means than if each single value 
carried equal Weight. Least-squares means for each group 
Were calculated, and a multiple comparison betWeen these 
means Was made after applying a Tukey-Kramer adjustment 
for the p-values. 
EXAMPLE 6 
Reduction of Skin Tumor Development by Niacin Supple 
mentation 
Groups of 25 mice each Were fed the AIN76A rodent diet 
containing 10% corn oil and 30 mg niacin per kilogram diet, 
supplemented With 0, 0.1, 0.5, or 1.0% niacin. After three 
Weeks of this diet, dorsally shaved mice Were exposed to UV 
radiation for 30 min per day, ?ve days per Week for 22 
Weeks. This irradiation resulted in a cumulative exposure of 
mice to approximately 1.41><106 Jm‘2 of UVB radiation. 
Irradiated mice fed unsupplemented diets developed a 68% 
skin tumor incidence by 26.5 Weeks after the ?rst UV 
exposure (FIG. 1A). Diet supplementation With 0.1, 0.5, or 
1.0% niacin reduced this incidence to 60, 48, or 28%, 
respectively. This dose response yielded statistically signi? 
cant reduction in mice fed the 1.0% and 0.5% niacin 
supplemented diets (p=0.0257, Wilcoxon rank sum test). 
The results of the multiplicity of tumors are presented in 
FIG. 1B. Supplementation of the basal diet With 0.1, 0.5, or 
1.0% niacin reduced the number of tumors per mouse from 
0.72 to 0.6, 0.48, or 0.4%, respectively at 26.5 Weeks after 
the ?rst UV treatment. 
EXAMPLE 7 
Niacin Ingestion and Body Weights of UV-Irradiated Mice 
Niacin ingestion Was calculated from diet consumption 
recorded on 50% of the animals of each group. Unirradiated 
mice fed the basal diet ingested an average of 0.09+/—0.03 
mg niacin per day per mouse throughout the experiment, and 
UV irradiated mice had a similar food intake. As shoWn in 
Table 1, UV irradiated mice fed the 0.1, 0.5, or 1.0% niacin 
supplemented diets had average intakes of 2.54(+/—0.56), 
13.93(+/—3.3), or 28.89(+/—6.0) mg niacin per day per 
mouse, respectively throughout the study. These results 
demonstrate that there Was an increased amount of niacin 
ingestion in mice fed higher concentrations of niacin in their 
food. The body Weights of the UV-irradiated mice, With or 
Without supplemental niacin, Were similar (Table 1), sug 


















Consumed Dietary Niacin Ingested 
(g/mouse/ Niacin (mg/mouse/ Body Weight 
Treatment day) (g/kg diet) day) (grams) 
+UV 2.86 (0.55) 0.03 0.09 (0.02) 18.2 (0.54) 
+UV 2.47 (0.54) 1.03 2.54 (0.56) 18.2 (0.77) 
+0.1% 
Niacin 
+UV 2.77 (0.66) 5.03 13.93 (3.3) 18.07 (1.37) 
+05% 
Niacin 
+UV 2.88 (0.60) 10.03 28.89 (6.0) 18.55 (0.91) 
+1% 
Niacin 
Values shoWn are means, standard deviations are shoWn in parentheses. 
EXAMPLE 8 
In?uence of Niacin Suplementation on Photoimmunosup 
pression 
The reduced ability of UVB-irradiated mice to reject 
syngeneic antigenic tumor cells is mediated by photoimmu 
nosuppression. This response is measured by a passive 
transfer assay in Which splenocytes from a UV irradiated 
mouse are injected into a naive unirradiated mouse (Gensler, 
H L and Magdaleno, M, Nutr Cancer 15, 97—106, 1991). 
The accelerated groWth of tumor cells implanted in recipi 
ents of splenocytes from UV irradiated donors as compared 
With unirradiated donors is a measure of the amount of 
transferred photoimmunosuppression. The capacity of nia 
cin supplementation to prevent photoimmunosuppression 
Was measured in this experiment. 
Brie?y, mice Were fed supplemented diets (0, 0.1%, 0.5 %, 
or 1.0% niacin) for three Weeks before UV radiation treat 
ments began. UVB irradiation consisted of ?ve 30 minute 
exposures per Week for 11 Weeks. Splenic leukocytes (one 
organ equivalent) of UV irradiated mice Were injected 
intravenously into each of 15 naive recipients. Within 24 
hours, these mice Were challenged With an intradermal 
injection of 5><105 UVM12 syngeneic antigenic tumor cells. 
The groWth of these tumor cells Was measured and presented 
in FIG. 2. The values displayed are the mean values +/—the 
standard deviation. As can be seen from FIG. 2, the mean 
tumor siZe Was 21.9 sq mm in recipients of splenocytes from 
unirradiated control mice, at 32 days after the tumor chal 
lenge. Recipients of splenocytes from UVB-irradiated mice 
treated With 0, 0.1%, 0.5%, or 1.0% niacin supplementation 
displayed mean tumor siZes of 91.6(+/—19.7), 79.8(+/—11.5), 
41.9 (+/—11.7), or 13.2(+/—4.1) sq mm, respectively. Analy 
sis of variances indicates that there Was a signi?cant treat 
ment effect on the tumor groWth rate (p=0.0001). Dunnett’s 
test shoWs that the tumor challenge groWth in recipients of 
splenocytes from UV irradiated mice treated With 0.5% or 
1.0% niacin Was signi?cantly loWer than that in recipients of 
splenocytes. This demonstrated that supplemental niacin in 
the range of 0.5—1.0%, prevented UV-induced photoimmu 
nosuppression as manifested by the ability of the recipient 
mice to reject antigenic tumors. 
EXAMPLE 9 
In?uence of Niacin Supplementation of Skin NAD Levels 
UV exposure Was directed to the dorsal shaved skin of 
treated mice. To assess the ability of ingested niacin to 
enhance NAD levels in UV irradiated as Well as in unirra 
diated skin, both unirradiated ventral skin and dorsal UV 
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irradiated skin Were collected. For each mouse, either one, 
tWo, or three skin samples Were collected at different sites 
form both the dorsal and ventral surfaces at 4.5 Weeks post 
UV treatment. The samples Were extracted to measure total 
NAD, and these values Were expressed relative to protein 
content to normaliZe the data. 
The results, shoWn in FIG. 3, shoW that niacin supple 
mentation elevates cellular NAD. When the cellular NAD 
levels Were plotted against the diet niacin level, it Was found 
that the relationship of niacin concentration in the diet to 
NAD in skin ?ts a logarithmic function. This logarithmic ?t 
suggested that NAD content approaches saturation at 
0.5—1.0% niacin supplementation. UV-irradiated mice 
receiving 0.5 and 1.0% niacin supplementation had signi? 
cantly higher skin NAD content than UV-irradiated mice 
receiving no additional niacin (p<0.0001 for dorsal skin, 
p=0.0114 for ventral skin, in 0.5% niacin supplemented 
mice; and p=0.0025 for dorsal skin, p=0.0017 for ventral 
skin, in 1.0% supplemented mice). The increase in NAD/ 
protein ratios appears greater for the ventral skin than the 
dorsal skin in the 1.0% niacin group, although neither value 
is signi?cantly different from values in the 0.5% niacin 
group. This suggests that a niacin concentration in the diet 
of 0.5 to 1% approach cutaneous NAD saturation. 
Oral niacin administration may prevent photoimmuno 
suppression and photocarcinogenesis by a number of mecha 
nisms. For example, oral niacin may modulate 1) ADP 
ribose transfer reactions that are knoWn to affect base 
excision repair, 2) p53 expression, Which is important in 
nucleotide excision repair, and 3) apoptosis (Ménissier de 
Murcia, J et al., Proc Natl Acad Sci, USA 94, 7303—7307; 
1997; Ford, J M and HanaWalt, P C et al., JBiol Chem 272, 
28073—28080, 1997; Ziegler, Aet al., Nature 372, 773—776, 
1994.). Poly(ADP-ribose) polymerase is required in base 
excision repair, the pathWay for repair of oxidative DNA 
damage, such as that induced by the UVA (320—400 nm) 
portion of UV radiation (Ménissier de Murcia, J et al., Proc 
Natl Acad Sci, USA 94, 7303—7307; Demple, B and 
Harrison, L, Annu Rev Biochem 63, 915—948, 1994; Kvam, 
E and Tyrrell, R M, Carcinogenesis 18, 2379—2348, 1997). 
Expression of p53 is necessary for ef?cient nucleotide 
excision repair of cyclobutane pyrimidine dimers and 6-4 
photoproducts from DNA damaged by the UVC (200—280 
nm) and UVB (280—320 nm) Wavelengths of UV radiation 
(Ford, J M and HanaWalt, P C et al., J Biol Chem 272, 
28073—28080, 1997; Rosentstein, B S, and Mitchell, D L, 
Photochem Photobiol 45, 775—780, 1987). NAD, the major 
metabolite of niacin, is a substrate for PARP, a nuclear 
enZyme Which binds to, and is activated by DNA strand 
scissions (James, M R and Lehman, A R, Biochem 21, 
4007—4013, 1982). PARP interacts With numerous proteins 
involved in DNA repair, including XRCCI, DNA ligase III, 
and p53 (Masson, M et al., Mol Cell Biol 18, 3563—3571, 
1998; VaZiri, H et al., EMBO 16, 6018—6033, 1997). PARP 
activity can be limited by NAD concentration (Zhang, J Z et 
al., J Nutr 123: 1349—1355, 1993). The experiments dem 
onstrate that niacin ingestion can determine NAD concen 
tration in the skin, as had been previously reported in a 
number of human tissues (Canner, P H et al., J Am Coll 
Cardio 8, 1245—1255, 1986; Demple, B and Harrison, L, 
Annu Rev Biochem 63, 915—948, 1994). Exposure of normal 
human ?broblasts to UV radiation results in activation of 
PARP and concomitant utiliZation of NAD (Gensler, H L, J 
Cancer Res Clin Oncol 117, 345—350, 1991; Jacobson, E L 
et al., J Biol Chem 258, 103—107, 1983). Chinese hamster 
lung ?broblast cells With reduced NAD content display 














response to etoposide, a topoisomerase II inhibitor that 
customarily results in increased p53 expression (Whitacre, C 
M et al., Cancer res 55: 3697—3701, 1995). This p53 
doWn-regulation has also been demonstrated for human lung 
?broblasts, skin ?broblasts, and mammary epithelial cells. 
P53 plays a critical role in skin squamous cell 
carcinogenesis, as evidenced by the presence of p53 muta 
tions in over 90% of human squamous cell carcinomas of the 
skin (Brash, D E, et al., Proc Natl Acad Sci, USA 88, 
10124—10128, 1991). The occurrence of these mutations in 
the early actinic keratotic stage of skin cancer suggests that 
p53 mutations are frequently an initiating step in cutaneous 
squamous cell carcinoma (Ziegler, A et al., Nature 372, 
773—776, 1994). The p53 protein is a transcription factor 
Which has an increased protein half-life in murine kerati 
nocytes exposed to UVB radiation (Liu, M et al., Carcino 
genesis 15, 1089—1092, 1994). One of the doWnstream 
genes activated by p53 in UVB/A irradiated keratinocytes is 
the WAF1/CIP 1 gene (Liu, M and Pelling, J C Oncogene 10, 
1955—1960, 1995). Its gene product, p21WAF1/CIP1, is a 
cyclin dependent kinase inhibitor that causes a G1 cell-cycle 
arrest by inhibiting the activity of the cyclin/cdK family 
(Xiong, Y et al., Nature 366, 701—704, 1993). It has been 
proposed that cell cycle arrest alloWs time for DNA repair 
before DNA replication. The p53 protein binds to DNA 
single strand scissions. PARP binds to the p53 protein as 
Well as to DNA strand scissions in vivo, and the complex 
retains its DNAbinding capacity (VaZiri, H et al., EMBO 16, 
6018—6033, 1997; James, M R and Lehman, A R, Biochem 
21, 4007—4013, 1982). Inhibition of PARP by 1,5 
dihydroxyisoquinoline prevents p53 dependent induction of 
P21Waf1/CIP1 in human myelogenous leukemia cells exposed 
to y-radiation (VaZiri, H et al., EMBO 16, 6018—6033, 1997), 
suggesting that PARP activity is required for activation of 
P21Waf1/CIP1 transcription by p53 protein. De?ciency of p53 
is knoWn to result in reduced nucleotide excision repair of 
UV-induced cyclobutane pyrimidine dimers and 6-4 photo 
products in total genomic DNA of human ?broblasts and in 
increased UV mutagenesis in murine ?broblasts (Ford, J M 
and HanaWalt, P C et al., J Biol Chem 272, 28073—28080, 
1997; Yuan, J et al., Carcinogenesis 16, 2295—2300, 1995). 
Cyclobutane pyrimidine dimers and 6-4 pyrimidine photo 
products are produced in the DNA of cells exposed to UVB 
radiation (Rosentstein, B S, and Mitchell, D L, Photochem 
Photobiol 45, 775—780, 1987). Additionally, inactivation of 
p53 in mouse skin reduces the appearance of apoptotic 
keratinocytes generated by UVB irradiation (Ziegler, A et 
al., Nature 372, 773—776, 1994). The apoptotic killing of 
cells containing extensive UV-induced DNA damage is 
thought to remove precancerous cells from the skin. These 
activities of p53 suggest that doWn-regulation of the p53 
response to UV irradiation by NAD de?ciency could lead to 
reduced induction of p21mf1/CIP1, decreased cell cycle 
arrest, decreased nucleotide excision repair, increased 
mutagenesis, and decreased apoptosis of severely 
UV-damaged cells, all resulting in enhanced photocarcino 
genesis. 
As a substrate for PARP, decreased NAD may in?uence 
repair of oxidative DNA damage induced by sunlight. The 
longer UV Wavelengths, above 334 nm and near visible 
radiations, cause extensive oxidative DNA damage (Kvam, 
E and Tyrrell, R M, Carcinogenesis 18, 2379—2348, 1997). 
Many DNAbase damages generated by oxidative processes, 
ioniZing radiation, or by simple alkylating agents are cor 
rected by base excision repair (Klungland, A and Lindahl, T, 
EMBO 16, 3341—3348, 1997; Seeberg, E et al., Trends 
Biochem Sci 20, 391—397, 1995; Demple, B and Harrison, L, 
US 6,495,537 B1 
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Annu Rev Biochem 63, 915—948, 1994). PARP has been 
implicated in the base excision repair pathway in vivo since 
PARP knockout mice are highly sensitive to alkylating 
agents and to y-radiation (Ménissier de Murcia, J et al., Proc 
Natl Acad Sci, USA 94, 7303—7307, 1997). By binding to 
DNA strand scissions and to base excision repair proteins 
XRCC1, DNA polymerase [3, and DNA ligase III, PARP 
detects DNA strand breaks and is thought to recruit proteins 
to form a multiprotein repair complex to process the strand 
scissions (Masson, M et al., Mol Cell Biol 18, 3563—3571, 
1998). Niacin supplementation may also protect against 
oxidative DNA damage by acting as an antioxidant (Kamat, 
J P and Devasagayam, T P, Chem Biol Interact 99, 1—16, 
1996). 
In summary, our results demonstrate that niacin supple 
mentation inhibits photocarcinogenesis and photoimmuno 
suppression in mice. Furthermore, ingestion of niacin leads 
to increased levels of NAD in skin. This increase Was 
evident even in skin Which had been repeatedly exposed to 
UV radiation (an agent knoWn to enhance NAD 
consumption). These results suggest that prevention of skin 
carcinogenesis by supplemental niacin results from block 
age of both UV-induced photoimmunosuppression and of 
cutaneous NAD depletion. Maintenance of NAD levels in 
skin With consequent PARP enhancement of base excision 
repair or UV induced oxidative DNA damage likely con 
tributes to the skin cancer prevention capacity of supple 
mental niacin. 
Other embodiments and uses of the invention Will be 
apparent to those skilled in the art from consideration of the 
speci?cation and practice of the invention disclosed herein. 
All US. patents and applications and other references noted 
herein are speci?cally incorporated by reference. The speci 
?cation and examples should be considered exemplary only 
With the true scope and spirit of the invention indicated by 







1. A method for inhibiting photocarcinogenesis or photo 
immunosuppression in a subject comprising administering a 
pharmaceutical composition consisting essentially of niacin 
to a subject in need thereof Wherein said niacin is in an 
amount effective to inhibit photocarcinogenesis or photoim 
munosuppression in said subject. 
2. The method of claim 1, Wherein said subject is a 
mammal. 
3. The method of claim 2 Wherein said mammal is a 
human. 
4. The method of claim 1, Wherein said administration 
comprises betWeen about 1 mg niacin per kilogram of 
subject Weight to about 100 mg per kilogram of subject 
Weight. 
5. The method of claim 1, Wherein said administration 
comprises betWeen about 10 mg niacin per kilogram of 
subject Weight and about 40 mg per kilogram of subject 
Weight. 
6. The method of claim 1, Wherein said photocarcinogen 
esis or photoimmunosuppression is by sunlight or ultraviolet 
radiation. 
7. The method of claim 1, Wherein said pharmaceutical 
composition further comprises a pharmaceutically accept 
able carrier. 
8. The method of claim 1 Wherein said pharmaceutical 
composition comprising niacin is administered orally to said 
subject. 
9. The method of claim 1, Wherein the subject Will be 
exposed to a photocarcinogenic agent. 
10. The method of claim 1, Wherein the subject Will be 
exposed to a photoimmunosuppresive agent. 
